Q2-rapport
63 dagar sedan‧37min
Orderdjup
Nasdaq Stockholm
Antal
Köp
24
Sälj
Antal
464
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
-VWAP
Lägst
-Omsättning ()
VWAP
Högst
-Lägst
-Omsättning ()
Mäklarstatistik
Ingen data hittades
Företagshändelser
| Nästa händelse | |
|---|---|
| 2025 Q3-rapport | 23 okt. |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 15 juli | |
| 2024 Årsstämma | 15 maj | |
| 2025 Q1-rapport | 24 apr. | |
| 2024 Q4-rapport | 6 feb. | |
| 2024 Q3-rapport | 24 okt. 2024 |
Data hämtas från Millistream, Quartr
Kunder har även besökt
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
1 sep. · Ändrad1 sep. · ÄndradJaha då har en första post gått in på detta bolag. Med tanke på SEB kommentaren för en tid sedan kan jag inte annat än tro att ledningen har förstått och ger järnet att komma ikapp om det nu behövs.... Om man ser på hur resultaträkningen ser ut så ser det betydligt bättre ut än i många andra inom samma nisch. Hur ser ni andra på detta bolag ? https://www.nordnet.se/marknaden/nyheter/3c07e17f-91a8-45c7-b3a7-1c0bf6520d6c
19 maj·Aktierna steg med 30 % mitt i veckan utan några nyheter, vilket utlöste spekulationer om privata aktier och drev dess aktieägarbas med EQT:s Thomas von Koch, Jan Ståhlberg och tidigare VD Christian Kinch. https://nordicedge.substack.com/p/monday-morning-espresso-w2025
31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradDet var jo ikke så godt med et tab på 9 mio kr med en omsætning på 55 mio. Hvor stor en omsætning skal der da til for at generere et overskud? Jeg har bemærket at omsætningen faktisk er vokset pænt år for år siden 2015, men kun ét år, er det lykkes at generere et lille overskud. De andre år har kørt med små underskud. Hvordan skal det så forstås, når VD skriver: " vi har skapat värdet för (..... ) og aktieägare"? Kursen er steget, ja, men indtjeningen i virksomheden har jo manglet, så den udmelding fra VD, synes jeg ikke om, når det omvendte er tilfældet. I givet fald er væksten på intern værdi i selskabet, men egenkapitalen er ikke steget. Jeg tror BAC skal have kigget på deres indtjening på produkterne eller evt. deres omkostningsniveau, for i mine øjne tjener de simpelt hen for lidt i.fht. en iøvrigt ret fin omsætning.
31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradVad tror ni om följande konkurrens? https://www.svt.se/nyheter/lokalt/vast/chalmersforskare-bakom-coronadodande-uppfinning
31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradIntressant delning, bra med alternativ. Tar några år att få i hop en organisation.
31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradHydrocyn® aqua inactivates the coronavirus causing COVID-19 TUE, JUN 02, 2020 16:40 CET https://news.cision.com/bactiguard-holding-ab--publ-/r/hydrocyn--aqua-inactivates-the-coronavirus-causing-covid-19,c3126504 The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal functions. In collaboration with the Swedish National Veterinary Institute (SVA), tests have been conducted with Hydrocyn on a viral culture of the new corona virus (SARS-CoV-2) that causes COVID-19. The result shows that 99.9% of the virus particles were inactivated – which means, they were no longer functional and thus not contagious. “The result is important in the fight against the spread of COVID-19. There is no vaccine yet and no effective COVID-19 drugs are available, so there is great need for effective prevention. Health care and the public need access to products that protect against the new coronavirus. We are therefore pleased that we have been able to prove that Hydrocyn is effective against this new virus and hope that we will soon be able to offer it to Swedish consumers,” says Stefan Grass, Bactiguard's Chief Medical Officer, MD PhD and formerly active as specialist physician in anesthesia and intensive care. “In addition to documented effects against coronavirus, Hydrocyn is also effective against bacteria and fungi. Unlike disinfectants based on, for example, alcohol, Hydrocyn is also kind to the body and does not cause irritation or tissue damage,” adds Stefan Grass. Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-02, at. 16.40. For further information, please contact: Stefan Grass, Chief Medical Officer and Deputy CEO e-mail stefan.grass@bactiguard.se, mobile +46 707 25 24 48 Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80 About Hydrocyn® aqua Bactiguard launched Hydrocyn® aqua in Sweden on March 12. Hydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants, Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency. About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about how Bactiguard saves lives at www.bactiguard.com
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Q2-rapport
63 dagar sedan‧37min
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- 1 sep. · Ändrad1 sep. · ÄndradJaha då har en första post gått in på detta bolag. Med tanke på SEB kommentaren för en tid sedan kan jag inte annat än tro att ledningen har förstått och ger järnet att komma ikapp om det nu behövs.... Om man ser på hur resultaträkningen ser ut så ser det betydligt bättre ut än i många andra inom samma nisch. Hur ser ni andra på detta bolag ? https://www.nordnet.se/marknaden/nyheter/3c07e17f-91a8-45c7-b3a7-1c0bf6520d6c
- 19 maj·Aktierna steg med 30 % mitt i veckan utan några nyheter, vilket utlöste spekulationer om privata aktier och drev dess aktieägarbas med EQT:s Thomas von Koch, Jan Ståhlberg och tidigare VD Christian Kinch. https://nordicedge.substack.com/p/monday-morning-espresso-w2025
- 31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradDet var jo ikke så godt med et tab på 9 mio kr med en omsætning på 55 mio. Hvor stor en omsætning skal der da til for at generere et overskud? Jeg har bemærket at omsætningen faktisk er vokset pænt år for år siden 2015, men kun ét år, er det lykkes at generere et lille overskud. De andre år har kørt med små underskud. Hvordan skal det så forstås, når VD skriver: " vi har skapat värdet för (..... ) og aktieägare"? Kursen er steget, ja, men indtjeningen i virksomheden har jo manglet, så den udmelding fra VD, synes jeg ikke om, når det omvendte er tilfældet. I givet fald er væksten på intern værdi i selskabet, men egenkapitalen er ikke steget. Jeg tror BAC skal have kigget på deres indtjening på produkterne eller evt. deres omkostningsniveau, for i mine øjne tjener de simpelt hen for lidt i.fht. en iøvrigt ret fin omsætning.
- 31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradVad tror ni om följande konkurrens? https://www.svt.se/nyheter/lokalt/vast/chalmersforskare-bakom-coronadodande-uppfinning31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradIntressant delning, bra med alternativ. Tar några år att få i hop en organisation.
- 31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradHydrocyn® aqua inactivates the coronavirus causing COVID-19 TUE, JUN 02, 2020 16:40 CET https://news.cision.com/bactiguard-holding-ab--publ-/r/hydrocyn--aqua-inactivates-the-coronavirus-causing-covid-19,c3126504 The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal functions. In collaboration with the Swedish National Veterinary Institute (SVA), tests have been conducted with Hydrocyn on a viral culture of the new corona virus (SARS-CoV-2) that causes COVID-19. The result shows that 99.9% of the virus particles were inactivated – which means, they were no longer functional and thus not contagious. “The result is important in the fight against the spread of COVID-19. There is no vaccine yet and no effective COVID-19 drugs are available, so there is great need for effective prevention. Health care and the public need access to products that protect against the new coronavirus. We are therefore pleased that we have been able to prove that Hydrocyn is effective against this new virus and hope that we will soon be able to offer it to Swedish consumers,” says Stefan Grass, Bactiguard's Chief Medical Officer, MD PhD and formerly active as specialist physician in anesthesia and intensive care. “In addition to documented effects against coronavirus, Hydrocyn is also effective against bacteria and fungi. Unlike disinfectants based on, for example, alcohol, Hydrocyn is also kind to the body and does not cause irritation or tissue damage,” adds Stefan Grass. Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-02, at. 16.40. For further information, please contact: Stefan Grass, Chief Medical Officer and Deputy CEO e-mail stefan.grass@bactiguard.se, mobile +46 707 25 24 48 Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80 About Hydrocyn® aqua Bactiguard launched Hydrocyn® aqua in Sweden on March 12. Hydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants, Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency. About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about how Bactiguard saves lives at www.bactiguard.com
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Nasdaq Stockholm
Antal
Köp
24
Sälj
Antal
464
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
-VWAP
Lägst
-Omsättning ()
VWAP
Högst
-Lägst
-Omsättning ()
Mäklarstatistik
Ingen data hittades
Kunder har även besökt
Företagshändelser
| Nästa händelse | |
|---|---|
| 2025 Q3-rapport | 23 okt. |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 15 juli | |
| 2024 Årsstämma | 15 maj | |
| 2025 Q1-rapport | 24 apr. | |
| 2024 Q4-rapport | 6 feb. | |
| 2024 Q3-rapport | 24 okt. 2024 |
Data hämtas från Millistream, Quartr
Q2-rapport
63 dagar sedan‧37min
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Företagshändelser
| Nästa händelse | |
|---|---|
| 2025 Q3-rapport | 23 okt. |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 15 juli | |
| 2024 Årsstämma | 15 maj | |
| 2025 Q1-rapport | 24 apr. | |
| 2024 Q4-rapport | 6 feb. | |
| 2024 Q3-rapport | 24 okt. 2024 |
Data hämtas från Millistream, Quartr
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- 1 sep. · Ändrad1 sep. · ÄndradJaha då har en första post gått in på detta bolag. Med tanke på SEB kommentaren för en tid sedan kan jag inte annat än tro att ledningen har förstått och ger järnet att komma ikapp om det nu behövs.... Om man ser på hur resultaträkningen ser ut så ser det betydligt bättre ut än i många andra inom samma nisch. Hur ser ni andra på detta bolag ? https://www.nordnet.se/marknaden/nyheter/3c07e17f-91a8-45c7-b3a7-1c0bf6520d6c
- 19 maj·Aktierna steg med 30 % mitt i veckan utan några nyheter, vilket utlöste spekulationer om privata aktier och drev dess aktieägarbas med EQT:s Thomas von Koch, Jan Ståhlberg och tidigare VD Christian Kinch. https://nordicedge.substack.com/p/monday-morning-espresso-w2025
- 31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradDet var jo ikke så godt med et tab på 9 mio kr med en omsætning på 55 mio. Hvor stor en omsætning skal der da til for at generere et overskud? Jeg har bemærket at omsætningen faktisk er vokset pænt år for år siden 2015, men kun ét år, er det lykkes at generere et lille overskud. De andre år har kørt med små underskud. Hvordan skal det så forstås, når VD skriver: " vi har skapat värdet för (..... ) og aktieägare"? Kursen er steget, ja, men indtjeningen i virksomheden har jo manglet, så den udmelding fra VD, synes jeg ikke om, når det omvendte er tilfældet. I givet fald er væksten på intern værdi i selskabet, men egenkapitalen er ikke steget. Jeg tror BAC skal have kigget på deres indtjening på produkterne eller evt. deres omkostningsniveau, for i mine øjne tjener de simpelt hen for lidt i.fht. en iøvrigt ret fin omsætning.
- 31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradVad tror ni om följande konkurrens? https://www.svt.se/nyheter/lokalt/vast/chalmersforskare-bakom-coronadodande-uppfinning31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradIntressant delning, bra med alternativ. Tar några år att få i hop en organisation.
- 31 jan. 2022 · Ändrad31 jan. 2022 · ÄndradHydrocyn® aqua inactivates the coronavirus causing COVID-19 TUE, JUN 02, 2020 16:40 CET https://news.cision.com/bactiguard-holding-ab--publ-/r/hydrocyn--aqua-inactivates-the-coronavirus-causing-covid-19,c3126504 The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal functions. In collaboration with the Swedish National Veterinary Institute (SVA), tests have been conducted with Hydrocyn on a viral culture of the new corona virus (SARS-CoV-2) that causes COVID-19. The result shows that 99.9% of the virus particles were inactivated – which means, they were no longer functional and thus not contagious. “The result is important in the fight against the spread of COVID-19. There is no vaccine yet and no effective COVID-19 drugs are available, so there is great need for effective prevention. Health care and the public need access to products that protect against the new coronavirus. We are therefore pleased that we have been able to prove that Hydrocyn is effective against this new virus and hope that we will soon be able to offer it to Swedish consumers,” says Stefan Grass, Bactiguard's Chief Medical Officer, MD PhD and formerly active as specialist physician in anesthesia and intensive care. “In addition to documented effects against coronavirus, Hydrocyn is also effective against bacteria and fungi. Unlike disinfectants based on, for example, alcohol, Hydrocyn is also kind to the body and does not cause irritation or tissue damage,” adds Stefan Grass. Bactiguard launched Hydrocyn in the Swedish market in mid-March and received customer orders, including from the Police Authority, in the first days after the launch, at a total value of just over SEK 20 million. This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-06-02, at. 16.40. For further information, please contact: Stefan Grass, Chief Medical Officer and Deputy CEO e-mail stefan.grass@bactiguard.se, mobile +46 707 25 24 48 Cecilia Edström, CEO, e-mail cecilia.edstrom@bactiguard.se, phone: +46 8 440 58 80 About Hydrocyn® aqua Bactiguard launched Hydrocyn® aqua in Sweden on March 12. Hydrocyn® aqua is an advanced disinfectant that is pH-neutral and water-based and can be used as a disinfectant solution for, for example, skin and surfaces. Unlike alcohol-based disinfectants, Hydrocyn® aqua is not irritating, toxic or harmful to the body. It is also not flammable. The active substance (HOCl) is a natural part of the human immune system. The product is CE marked (approved in the EU), registered by the US FDA and approved by the Swedish Chemicals Agency. About Bactiguard Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about how Bactiguard saves lives at www.bactiguard.com
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Nasdaq Stockholm
Antal
Köp
24
Sälj
Antal
464
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
-VWAP
Lägst
-Omsättning ()
VWAP
Högst
-Lägst
-Omsättning ()
Mäklarstatistik
Ingen data hittades